| Literature DB >> 34079185 |
Chung Hyeok Lee1, Eun Mi Jin2, Hee Seok Seo1, Tae-Ui Ryu2, Seung Phil Hong1.
Abstract
BACKGROUND: Fractional picosecond lasers is effective for the treatment of wrinkles or acne scars.Entities:
Keywords: Diffractive optic element; Nd-YAG lasers; Picosecond; Skin rejuvenation
Year: 2021 PMID: 34079185 PMCID: PMC8137336 DOI: 10.5021/ad.2021.33.3.254
Source DB: PubMed Journal: Ann Dermatol ISSN: 1013-9087 Impact factor: 1.444
Characteristics of the subjects
| Variable | Wrinkle | Acne scar | Total |
|---|---|---|---|
| No. of subjects | 12 | 10 | 22 |
| Female | 12 (100) | 3 (30.0) | 15 (68.2) |
| Age (yr) | 47.4±9.9 | 30.4±10.4 | 39.6±13.2 |
| Height (cm) | 159.4±4.8 | 172.9±8.4 | 165.5±9.4 |
| Body weight (kg) | 57.2±5.1 | 71.2±16.5 | 63.6±13.6 |
| Body mass index (kg/m2) | 22.6±2.4 | 23.5±3.7 | 23.0±3.1 |
Values are presented as number (%) or mean±standard deviation.
Fig. 1(A, B) Mean improvement of global photographic assessment score of the three dermatologists. (A) Results of total subjects. (B) Subgroup analyses of subjects with acne scars and subjects with wrinkles. (C, D) Mean global assessment score of the subjects. (C) Results of total subjects. (D) Subgroup analyses of subjects with acne scars and subjects with wrinkles. Statistically significant improvements were observed after all treatment sessions and 2 months after the last treatment (week 14) compared to the baseline. GAIS: global aesthetic improvement scale. *p<0.05, compared to the baseline values; **p<0.01, compared to the baseline values.
Fig. 2Representative two-dimensional (2D) and three-dimensional (3D) digital photographs of (A~C) subjects with wrinkles and (D) subjects with acne scars taken by ANTERA 3D® at week 14. Compared to that at baseline, the subjects with wrinkle presented with reduced wrinkles and skin depression (A~C). Representative photographs of subjects with acne scars show reduced scar counts, depth, and affected areas (D).
Percent change in the profilometric measurements at week 14
| Subject group | Wrinkles | Acne scars | Overall subjects | ||
|---|---|---|---|---|---|
| Profilometry measurement (%) Wrinkles | |||||
| Wrinkles | |||||
| ΔIndentation | −9.53±8.84* | −11.66±12.16* | −10.50±10.27* | ||
| ΔMaximum depth | −9.90±12.68* | −19.01±12.52* | −14.05±13.15** | ||
| Texture | |||||
| ΔRoughness: Ra | −9.28±10.51* | −12.93±14.80* | −10.94±12.46* | ||
| ΔRoughness: Rq | −10.75±10.99* | −13.60±14.08* | −12.05±12.26* | ||
| ΔElevation span | −7.65±24.52 | −12.31±12.00 | −9.77±19.55 | ||
| Depressions | |||||
| ΔVolume | −23.58±28.70* | −24.08±36.71 | −23.81±31.77* | ||
| ΔMaximum depth | −10.02±12.56* | −19.27±12.58* | −14.22±13.14** | ||
| ΔAffected area | −21.71±27.5* | −20.14±34.18* | −21.0±29.90* | ||
| Pores | |||||
| ΔVolume | −29.74±47.94* | −28.94±41.99* | −29.38±44.27* | ||
| ΔMaximum depth | −14.23±14.36* | −15.62±20.72* | −14.86±17.11* | ||
| ΔCount | −18.58±34.07* | −17.05±32.23* | −17.88±32.46* | ||
| ΔDensity | −18.57±34.09* | −17.05±32.24* | −17.88±32.48* | ||
Values are presented as mean±standard deviation. This data represents the relative value depicting the percentage change from baseline. *p<0.05, **p<0.01 compared to the baseline values.
Fig. 3Skin viscoelasticity as measured using Cutometer® at week 14. The gross elasticity (R2) (A) and skin firmness (R7) (C) significantly improved in all subjects. However, the net elasticity (R5) (B) showed significant improvement in only subjects with acne scars. *p<0.05, compared to the baseline values.
Summary of the adverse events
| Adverse event | After the first laser treatment | After the second laser treatment | After the third laser treatment | |
|---|---|---|---|---|
| Erythema | 22 (100) | 20 (90.9) | 22 (100) | |
| Transient | 20 (90.9) | 20 (90.9) | 22 (100) | |
| (17/3/0)† | (12/8/0)† | (13/9/0)† | ||
| Persistent | 2 (9.1) | 0 | 0 | |
| (0/2/0)† | ||||
| Pruritus | 19 (86.4) | 16 (72.7) | 17 (77.3) | |
| Transient | 15 (68.2) | 13 (59.1) | 16 (72.7) | |
| (10/5/0)† | (9/4/0)† | (14/2/0)† | ||
| Persistent | 4 (18.2) | 3 (13.6) | 1 (4.5) | |
| (1/3/0)† | (1/2/0)† | (0/1/0)† | ||
| Petechiae | 13 (59.1) | 14 (63.6) | 13 (59.1) | |
| Transient | 10 (45.5) | 11 (50.0) | 13 (59.1) | |
| (9/1/0)† | (8/3/0)† | (10/3/0)† | ||
| Persistent | 3 (13.6) | 3 (13.6) | 0 (0) | |
| (2/1/0)† | (2/1/0)† | |||
| Pustules | 12 (54.5) | 5 (22.7) | 5 (22.7) | |
| Transient | 7 (31.8) | 4 (18.2) | 3 (13.6) | |
| (5/2/0)† | (4/0/0)† | (2/1/0)† | ||
| Persistent | 5 (22.8) | 1 (4.5) | 2 (9.1) | |
| (4/1/0)† | (1/0/0)† | (0/2/0)† | ||
| Papules | 0 (0%) | 1 (4.5) | 0 (0) | |
| Transient | 0 | 1 (4.5) | 0 | |
| (1/0/0)† | ||||
| Persistent | 0 | 0 | 0 | |
Transient adverse events resolved in 1 to 3 days; persistent adverse event persisted for >3 days. Values are presented as number (%) or number only. †Indicates (mild/moderate/severe case number).